文献速递浆细胞疾病

ABBV-383(一种B细胞成熟抗原×CD3双特异性T细胞重定向抗体)在复发/难治性多发性骨髓瘤患者中的I期首次人体研究

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma.
PubMed 文献 · J Clin Oncol · 2022-08-27

这项I期首次人体剂量递增/扩展研究评估了ABBV-383在复发/难治性多发性骨髓瘤(RRMM)患者中的安全性和疗效。截至2022年1月8日,124例患者接受ABBV-383治疗,最常见血液学不良事件为中性粒细胞减少(37%)和贫血(29%),最常见非血液学不良事件为细胞因子释放综合征(57%)和乏力(30%)。所有可评估疗效患者(n=122)的客观缓解率(ORR)为57%,≥非常好的部分缓解(≥VGPR)率为43%;≥40 mg剂量组(n=79)的ORR为68%,≥VGPR率为54%。

要点

  • ABBV-383每3周静脉给药一次,无需阶梯剂量,在RRMM患者中耐受良好。
  • 所有剂量可评估患者(n=122)ORR为57%,≥VGPR率为43%。
  • ≥40 mg剂量组(n=79)ORR为68%,≥VGPR率为54%。

核心结论

  • ABBV-383在RRMM患者中耐受良好,≥40 mg剂量组的ORR为68%。
  • 该新型疗法在经重度预处理患者中显示出有前景的初步抗肿瘤活性,需进一步临床评估。

研究设计与样本

  • I期首次人体剂量递增/扩展研究(ClinicalTrials.gov标识符:NCT03933735)。
  • 纳入既往接受≥3线治疗(包括蛋白酶体抑制剂、免疫调节药物和抗CD38单克隆抗体)的RRMM患者。
  • ABBV-383每3周静脉给药一次,输注1-2小时,无需阶梯剂量。
  • 剂量递增采用3+3设计并允许回填(允许患者内递增至最高安全剂量),随后启动剂量扩展。
  • 截至2022年1月8日,共124例患者接受ABBV-383治疗(剂量递增[0.025-120 mg],n=73;剂量扩展[60 mg],n=51),中位年龄68岁(范围35-92岁)。

主要发现

  • 最常见的血液学治疗中出现的不良事件(TEAE)为中性粒细胞减少(所有级别:37%)和贫血(29%)。
  • 最常见的非血液学TEAE为细胞因子释放综合征(57%)和乏力(30%)。
  • 报告了7例因TEAE导致的死亡,研究者认为均与研究药物无关。
  • 所有可评估疗效患者(n=122;所有剂量)的ORR为57%,≥VGPR率为43%。
  • 60 mg剂量扩展队列(n=49)的ORR为59%,≥VGPR率为39%;≥40 mg剂量递增联合剂量扩展队列(n=79)的ORR为68%,≥VGPR率为54%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出该疗法在经重度预处理患者中的初步抗肿瘤活性需进一步临床评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: ABBV-383, a B-cell maturation antigen × CD3 T-cell engaging bispecific antibody, has demonstrated promising results in an ongoing first-in-human phase I study (ClinicalTrials.gov identifier: NCT03933735) in patients with relapsed/refractory multiple myeloma (RRMM). Herein, we report safety and efficacy outcomes of this phase I dose escalation/expansion study. METHODS: Patients with RRMM (≥ three prior lines including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody) were eligible. ABBV-383 was administered intravenously over 1-2 hours once every 3 weeks, without any step dosing. A 3 + 3 design with backfilling for dose escalation was used (intrapatient escalation to highest safe dose permitted) followed by initiation of dose expansion. RESULTS: As of January 8, 2022, 124 patients (dose escalation [0.025-120 mg], n = 73; dose expansion [60 mg], n = 51) have received ABBV-383; median age was 68 years (range, 35-92 years). The most common hematologic treatment-emergent adverse events (TEAEs) were neutropenia (all grades: 37%) and anemia (29%). The most common nonhematologic TEAEs were cytokine release syndrome (57%) and fatigue (30%). Seven deaths from TEAEs were reported with all considered unrelated to study drug by the investigator. For all efficacy-evaluable patients (n = 122; all doses), the objective response rate (ORR) was 57% and very good partial response (VGPR) or better (≥ VGPR) rate was 43%. In the 60 mg dose expansion cohort (n = 49), the ORR and ≥ VGPR rates were 59% and 39%, respectively; and in the ≥ 40 mg dose escalation plus dose expansion cohorts (n = 79) were 68% and 54%, respectively. CONCLUSION: ABBV-383 in patients with RRMM was well tolerated with an ORR of 68% at doses ≥ 40 mg. This novel therapy's promising preliminary antitumor activity in heavily pretreated patients warrants further clinical evaluation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. D'Souza A, Shah N, Rodriguez C, et al. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2022. PMID: 36029527. doi:10.1200/JCO.22.01504

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。